Global Market of Monoclonal Antibodies: Sales, Prices, Demand
https://doi.org/10.21686/2413-2829-2021-2-64-76
Abstract
Bio-pharmaceutics is one of the most science-intensive industries. Annually a lot of money is spent on applied research aimed at development and commercialization of new medications. Many pharmaceutical companies try to have in their product line or pipeline drugs on the basis of monoclonal antibodies, i.e. a class of biotechnological preparations that are used to combat oncologic and autoimmune diseases and are based on target therapy principle. Because of the high interest in bio-pharmaceutical industry on the part of businessmen, state and science any advanced data dealing with the situation inside the market can be useful for shaping the adequate picture of the present day condition and for making managerial decisions on state and private level. The article provides information about global sales of preparations based on monoclonal antibodies. Apart from sales in terms of money the author calculates the natural volume of products being sold based on price analysis of products. The article gives a list of preparations registered on EU and US markets rated by their sales. By analyzing preparation prices corrected to dosage it was possible to find the most expensive and the cheapest medications in their class. Information concerning the natural volume of drug being sold can help understand the scale of preparation production.
About the Author
D. A. Uvarov
Lomonosov Moscow State University
Russian Federation
Russian Federation
Danila A. Uvarov, Post-Graduate Student of the Department for Economics of Innovation
1 Leninskie gory, Moscow, 119991
References
1. Blackstone E. A., Fuhr J. P. Economics of Biosimilars. American Health & Drug Benefits, 2013, No. 6 (8), pp. 469–478.
2. Chen Q., Ayer T., Rose A. C., Nastoupil L. J., Flowers Ch. R. Comparing the CostEffectiveness of Rituximab Maintenance and Radio-Immunotherapy Consolidation Versus Observation Following First-Line Therapy in Follicular Lymphoma Patients. Value Health, 2015, Vol. 18 (2), pp. 189–197.
3. Ecker D. M., Jones S. D., Levine H. L. The Therapeutic Monoclonal Antibody Market. mAbs, 2015, Vol. 7 (1), pp. 9–14.
4. Goldsmith A. D., Varela F. E. Fragmentation in the Biopharmaceutical Industry. Drug Discovery Today, 2016, Vol 22 (2), pp. 1–7.
5. Grabowski H. G., DiMasi J. A., Long G. The Roles of Patents and Research and Development Incentives in Biopharmaceutical Innovation. Health Affairs, 2015, Vol. 34 (2), pp. 302–310.
6. Hammerschmidt N., Tscheliessnig A., Sommer R., Helk B., Jungbauer A. Economics of Recombinant Antibody Production Processes at Various Scales: Industry-Standard Compared to Continuous Precipitation. Biotechnology Journal, 2014, Vol. 9 (16), pp. 766–775.
7. Kelley B. D. Industrialization of mAb Production Technology: The bioprocessing industry at a crossroads. mAbs, 2009, Vol. 1 (5), pp. 443–452.
8. Levine H. L., Stock R., Lilja J. E., Gaasvik Å., Hummel H., Ransohoff T. C., Jones S. D. Single-Use Technology and Modular Construction Enabling Biopharmaceutical Facilities of the Future. BioProcess International, 2013, Vol. 11, pp. 40–45.
9. Lu R.-M., Hwang Y.-Ch., Liu I-J., Lee Ch.-Ch., Tsai H.-Z., Li H.-J., Wu H.-Ch. Development of Therapeutic Antibodies for the Treatment of Diseases. Journal of Biomedical Science, 2020, Vol. 27 (1), pp. 1–30.
10. March-Chorda I., Yague-Perales R. M. Biopharma business models in Canada. Drug Discovery Today, 2011, No. 16, pp. 654–658.
Review
For citations:
Uvarov D.A. Global Market of Monoclonal Antibodies: Sales, Prices, Demand. Vestnik of the Plekhanov Russian University of Economics. 2021;18(2):64-76. (In Russ.) https://doi.org/10.21686/2413-2829-2021-2-64-76
Views:
1119
Email this article 